Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 23 |
| Active Pipeline (Recruiting Now) | 10 (6) |
| Completed vs Stopped Early | 11 / 2 (8.7%) |
| Median Closed Actual Enrollment | 206 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| London Health Sciences Centre | London, Ontario | 4 |
| University of Alberta | Edmonton, Alberta | 4 |
| Ohio State University Comprehensive Cancer Center | Columbus, OH | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT03636295 | Low INR to Minimize Bleeding With Mechanical Valves Trial | Phase III | RECRUITING |
| NCT04284839 | The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial | Phase III | RECRUITING |
| NCT04774159 | Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk | Phase III | RECRUITING |
| NCT04324463 | Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Population Health Research Institute Interactive Dossier, benchmark peers in Cardiovascular and Thrombosis, or review the Healthcare Price & Patent Cliff Crosswalk.